Skip to main content

Table 2 Estimated odds of serious infection for treatment strategies compared to placebo

From: Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis

Treatment strategy Comparator Odds ratio Standard error 95% Confidence interval
Infliximab Placebo 1.36 0.45 0.57 3.27
Adalimumab Placebo 0.77 0.36 0.38 1.56
Certolizumab pegol Placebo 2.37 0.50 0.88 6.38
Natalizumab Placebo 0.80 0.40 0.37 1.73
Ustekinumab Placebo 0.40 0.49 0.16 1.05
Vedolizumab Placebo 0.75 0.38 0.36 1.58
Golimumab Placebo 1.71 0.67 0.46 6.31
Methotrexate Placebo 0.52 1.28 0.04 6.34
Azathioprine/6MP Placebo 1.43 0.61 0.43 4.76
Prednisone Placebo 1.92 0.85 0.36 10.21
Budesonide Placebo 1.99 1.65 0.08 50.97
Aminosalicylate Placebo 1.37 1.40 0.09 21.47
Antibiotic Placebo 1.01 1.07 0.12 8.34
Tacrolimus Placebo 1.19 2.02 0.02 62.32
Methotrexate + prednisone Placebo 2.94 1.45 0.17 50.23
Azathioprine/6MP + prednisone Placebo 2.37 1.76 0.07 75.25
Aminosalicylate + prednisone Placebo 7.32 2.41 0.06 832.34
Budesonide + prednisone Placebo 1.89 2.18 0.03 135.88
MMF + prednisone Placebo 4.14 2.07 0.07 241.50
Infliximab + azathioprine/6MP Placebo 1.10 0.65 0.31 3.97
Azathioprine/6MP + aminosalicylate Placebo 1.35 2.11 0.02 83.66
Natalizumab + inflximab Placebo 0.71 2.06 0.01 40.65
Infliximab + azathioprine/6MP + prednisone Placebo 0.32 2.33 0.00 30.40
  1. Abbreviations: 6MP 6-mercaptopurine, MMF mycophenolate mofetil
\